NASDAQ:KIN - Kindred Biosciences Stock Price, Forecast & News

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

Kindred Biosciences Inc (NASDAQ:KIN) issued its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by $0.02. The biopharmaceutical company had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.55 million. View Kindred Biosciences' Earnings History.

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Kindred Biosciences.

8 brokers have issued 12-month price objectives for Kindred Biosciences' stock. Their forecasts range from $8.50 to $25.00. On average, they anticipate Kindred Biosciences' stock price to reach $14.44 in the next twelve months. This suggests a possible upside of 53.1% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.

Media headlines about KIN stock have trended neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kindred Biosciences earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Kindred Biosciences.

Kindred Biosciences saw a increase in short interest in January. As of January 31st, there was short interest totalling 753,000 shares, an increase of 16.2% from the January 15th total of 648,200 shares. Based on an average trading volume of 126,400 shares, the short-interest ratio is presently 6.0 days. Approximately 2.1% of the shares of the stock are sold short. View Kindred Biosciences' Current Options Chain.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kindred Biosciences investors own include CorMedix (CRMD), bluebird bio (BLUE), Amicus Therapeutics (FOLD), Opko Health (OPK), Progenics Pharmaceuticals (PGNX), TherapeuticsMD (TXMD), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD) and Inovio Pharmaceuticals (INO).

Kindred Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Ariel Investments LLC (4.56%), Renaissance Technologies LLC (3.02%), State Street Corp (1.79%), UBS Group AG (0.37%), Bank of New York Mellon Corp (0.29%) and Charles Schwab Investment Management Inc. (0.25%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.

KIN stock was sold by a variety of institutional investors in the last quarter, including Ariel Investments LLC, Goldman Sachs Group Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for Kindred Biosciences.

KIN stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, State Street Corp, Cambridge Investment Research Advisors Inc., Edgewood Management LLC, UBS Group AG, Prudential Financial Inc., Barclays PLC and Banque Cantonale Vaudoise. View Insider Buying and Selling for Kindred Biosciences.

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KIN stock can currently be purchased for approximately $9.43.